NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

Phase 3

Completed

Conditions: Tuberculosis
HIV Infections

Interventions: Drug: Rifapentine (RPT)
Drug: Isoniazid (INH)
Dietary Supplement: Pyridoxine (Vitamin B6)

First Posted Date: 2011-07-28

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 3000

Registration Number: NCT01404312

Locations: 🇺🇸
University of Southern California CRS, Los Angeles, California, United States
🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
🇺🇸
Trinity Health and Wellness Center CRS, Dallas, Texas, United States

and more 42 locations

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

Recruiting

Conditions: Influenza
Zika

First Posted Date: 2011-07-01

Last Posted Date: 2025-06-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 5000

Registration Number: NCT01386424

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Immune Responses to Two Experimental HIV Vaccines in Healthy Adults

Phase 1

Completed

Conditions: HIV Negative
Adaptive Immunity
Innate Immunity

First Posted Date: 2011-07-01

Last Posted Date: 2019-12-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT01386489

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

Recruiting

Conditions: Chronic Mucocutaneous Candidiasis
APECED
Invasive Aspergillosis
CARD9

First Posted Date: 2011-07-01

Last Posted Date: 2025-05-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1200

Registration Number: NCT01386437

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Asthma Phenotypes in the Inner City

Completed

Conditions: Asthma
Rhinitis

Interventions: Drug: Guidelines-based asthma and rhinitis/rhinosinusitis therapy

First Posted Date: 2011-06-28

Last Posted Date: 2017-03-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 717

Registration Number: NCT01383941

Locations: 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
National Jewish Health, Denver, Colorado, United States

and more 6 locations

Biomarkers of Cockroach Sublingual Immunotherapy 2

Phase 1

Completed

Conditions: Perennial Allergic Rhinitis
Asthma

Interventions: Biological: Cockroach Sublingual Immunotherapy (SLIT) - Low Dose
Other: Placebo
Biological: Cockroach Sublingual Immunotherapy (SLIT) - High Dose

First Posted Date: 2011-06-27

Last Posted Date: 2014-06-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 99

Registration Number: NCT01380327

Locations: 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 2 locations

Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali

Terminated

Conditions: Tuberculosis, Pulmonary
Antitubercular Agents
Tuberculosis, Mulutidrug-Resistant
Extensibely Drug-Resistant Tuberculosis
Mycobacterium Tuberculous
Extensively Drug-Resistant

First Posted Date: 2011-06-27

Last Posted Date: 2018-04-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 34

Registration Number: NCT01381757

Locations: 🇲🇱
University of Bamako, Bamako, Mali
🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi, Bethesda, Maryland, United States

Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Plague

Interventions: Biological: Flagellin/F1/V
Other: Placebo

First Posted Date: 2011-06-27

Last Posted Date: 2016-01-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT01381744

Locations: 🇺🇸
Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States

The Role of Epigenetics in Inner City Asthma

Completed

Conditions: Asthma

First Posted Date: 2011-06-27

Last Posted Date: 2015-11-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT01382836

Locations: 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Boston University School of Medicine, Boston, Massachusetts, United States

and more 3 locations

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: Sub C gp140 Vaccine
Biological: MF59C.1 Adjuvant

First Posted Date: 2011-06-20

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT01376726

Locations: 🇺🇸
Seattle Vaccine and Prevention CRS, Seattle, Washington, United States
🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
Vanderbilt Vaccine (VV) CRS, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy